At stake in the ongoing patent dispute over the gene-editing tool are rights to the most important new biotechnology of the age and credit for inventing it. The CRISPR patents are back in play. On ...
CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results